Article Abstract

Association between CYP17A1 polymorphisms and response to abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review

Authors: Xiang Zhou, Yuxiao Zheng, Jianzhong Zhang, Chuanjie Zhang, Guiya Jiang, Si Sun, Xiao Li, Christian Carrie, Shahrokh F. Shariat, David S. Lopez, Torben K. Nielsen, on behalf of AME Urology Disease Collaborative Group


We aimed to summarize and clarify the association between cytochrome P450 17α-hydrolase (CYP17A1) polymorphisms and outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone. The databases of PubMed, EMBASE, and Web of Science were searched for relevant studies. Overall survival (OS) and/or progression-free survival (PFS) were calculated. Odds ratios (ORs) and/or hazard ratios (HRs) with 95% confidence interval (CI) were utilized to evaluate the strength of the association. A total of 3 studies including 204 patients were analyzed in this systematic review. It was shown that CYP17A1 copy number variations were related to the prognosis of mCRPC patients treated with abiraterone. In addition, rs2486758, a common single-nucleotide polymorphisms (SNPs) in CYP17A1, was significantly associated with a poor biochemical response and a faster biochemical progression. Our systematic review showed that CYP17A1 polymorphisms are associated with response to abiraterone in mCRPC patients. Further research is needed to translate these findings into clinical decisive parameters.